fda warning letter compounded semaglutide september 2025 & Tirzepatide 2025: Safe Use Guide FDA unleashes warning letters to

It is essential to monitor for adverse events such as hypoglycemic episodes and blood pressure changes when using semaglutide, particularly in individuals with cardiovascular disease or risk factors related to heart attack and stroke

The FDA said in October that it had received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products. The agency also warned that some compounders may be selling salt forms of semaglutide, which are different active ingredients than are in the approved drugs, and that counterfeit forms of Ozempic are being sold

Mild Allergic Symptoms Warranting Monitoring Some symptoms suggest a mild allergic component that bears watching but does not typically require immediate medical attention

Democrats are more likely to favor this proposal than Republicans or independents

Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment